-
Access Pharmaceuticals Inc. (OTCBB:ACCP), Dallas, Texas AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), Lexington, Mass. Business: Other AMAG licensed exclusive, U.S. commercialization rights to MuGard mucoadhesive oral rinse …
Published on 6/17/2013
-
Ahn-Gook Pharmaceutical Co. Ltd. (KOSDAQ:001540), Seoul, South Korea EffRx Pharmaceuticals S.A., Lausanne, Switzerland Business: Musculoskeletal EffRx granted Ahn-Gook exclusive rights to develop and commercialize …
Published on 6/17/2013
-
Alliance Pharma plc (LSE:APH), Chippenham, U.K. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Genitourinary Alliance's Alliance Pharmaceuticals Ltd. subsidiary acquired all rights to Syntometrine …
Published on 6/17/2013
-
Almirall S.A. (Madrid:ALM), Barcelona, Spain Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Cambridge, Mass. Business: Gastrointestinal Almirall launched Constella linaclotide in Germany, the U.K. and Nordic countries to …
Published on 6/17/2013
-
Aqua Pharmaceuticals LLC, West Chester, Pa. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Dermatology Aqua acquired U.S. rights to Verdeso 0.05% desonide foam from GlaxoSmithKline's Stiefel …
Published on 6/17/2013
-
Bio-Reference Laboratories Inc. (NASDAQ:BRLI), Elmwood Park, N.J. Business: Diagnostic Bio-Reference's GeneDX Inc. subsidiary said it will launch genetic tests as early as Aug. 1 for inherited cancers, including tests …
Published on 6/17/2013
-
Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506), Osaka, Japan Business: Cardiovascular Dainippon launched Avapro irbesartan 200 mg tablets in Japan to treat hypertension. The National Health Insurance (NHI) …
Published on 6/17/2013
-
Diaxonhit (Euronext:ALEHT), Paris, France XDx Inc., Brisbane, Calif. Business: Diagnostic XDx and Diaxonhit entered into a memorandum of agreement to grant Diaxonhit exclusive rights to market and perform XDx's AlloMap …
Published on 6/17/2013
-
Gene By Gene Ltd., Houston, Texas Business: Diagnostic Gene By Gene's DNATraits division said it would begin offering a test for $995 to detect breast cancer 1 early onset (BRCA1) and BRCA2 mutations. The company …
Published on 6/17/2013
-
Hologic Inc. (NASDAQ:HOLX), Bedford, Mass. Quest Diagnostics Inc. (NYSE:DGX), Madison, N.J. Business: Diagnostic The partners entered a five-year, non-exclusive deal to allow Quest to offer a broader range of Hologic's …
Published on 6/17/2013
-
IncellDx Inc., Menlo Park, Calif. Kindstar Global Co. Ltd., Beijing, China Business: Diagnostic IncellDx partnered with reference laboratory Kindstar to offer IncellDx's HPV OncoTect E6, E7 mRNA test to screen for …
Published on 6/17/2013
-
Oxford Gene Technology, Oxford, U.K. Business: Diagnostic OGT launched CytoSure Single Cell Aneuploidy array for pre-implantation genetic screening (PGS) to improve the chances of successful in vitro fertilization (IVF…
Published on 6/17/2013
-
Pathway Genomics Corp., San Diego, Calif. Business: Diagnostic Pathway Genomics said that it will launch in August its Hereditary Cancer DNA Insight test to analyze genes, including breast cancer 1 early onset (BRCA1) …
Published on 6/17/2013
-
Pfizer Inc. (NYSE:PFE), New York, N.Y. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Autoimmune The partners launched a subcutaneous formulation of rheumatoid arthritis drug Enbrel etanercept in …
Published on 6/17/2013
-
Questcor Pharmaceuticals Inc. (NASDAQ:QCOR), Anaheim, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Autoimmune, Endocrine/Metabolic, Renal Questcor acquired exclusive, worldwide rights, outside …
Published on 6/17/2013
-
Quinnova Pharmaceuticals Inc., Newtown, Pa. Suneva Medical Inc., San Diego, Calif. Business: Dermatology Suneva granted Quinnova co-promotion rights in the U.S. to ReFissa 0.05% tretinoin emollient cream, which is …
Published on 6/17/2013
-
Renaissance Acquisition Holdings LLC, Lake Forest, Ill. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Dermatology, Infectious GlaxoSmithKline granted Renaissance rights to market six approved …
Published on 6/17/2013
-
Zeria Pharmaceutical Co. Ltd. (Tokyo:4559), Tokyo, Japan Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Gastrointestinal Astellas launched Acofide acotiamide in Japan to treat functional dyspepsia. The …
Published on 6/17/2013
-
AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Business: Gastrointestinal AbbVie said FDA approved a 36,000 lipase-unit dose of Creon pancrelipase delayed-release capsules to treat pancreatic exocrine insufficiency (PEI). The …
Published on 6/10/2013
-
Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Eisai Co. Ltd. (Tokyo:4523; Osaka:4523), Tokyo, Japan Business: Endocrine/Metabolic Eisai launched twice-daily obesity drug Belviq lorcaserin from Arena in the…
Published on 6/10/2013
-
Asahi Kasei Pharma Corp., Tokyo, Japan Hisamitsu Pharmaceutical Co. Inc. (Tokyo:4530; Osaka:4530), Tosu, Japan Business: Genitourinary Hisamitsu said Neoxy oxybutynin has been listed on the Japanese National Health …
Published on 6/10/2013
-
Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Boehringer Ingelheim GmbH, Ingelheim, Germany Business: Cardiovascular Astellas and Boehringer's Nippon Boehringer Ingelheim Co. Ltd. launched Micamlo 80 mg telmisartan/5 …
Published on 6/10/2013
-
Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Tecnofarma International Ltd., Montevideo, Uruguay Business: Cancer Astellas granted Tecnofarma exclusive rights to distribute prostate cancer drug Xtandi enzalutamide in …
Published on 6/10/2013
-
Cipla Ltd., Mumbai, India Meda AB (SSE:MEDAA), Solna, Sweden Business: Inflammation Cipla and Meda added full rights in Latin and South America, the Middle East, Africa and Asia to 2008 and 2009 deals granting Meda …
Published on 6/10/2013
-
Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Business: Endocrine/Metabolic Kyowa said once-daily oral Onglyza saxagliptin has been listed on the Japanese National …
Published on 6/10/2013